Neuronetics to Present at the Piper Sandler 36th Annual Healthcare Conference
Neuronetics to Present at the Piper Sandler 36th Annual Healthcare Conference
Neuronetics, Inc. believes that mental health is as important as physical health. As a global leader in neuroscience, Neuronetics is redefining patient and physician expectations with its NeuroStar Advanced Therapy for Mental Health. NeuroStar is a non-drug, noninvasive treatment that can improve the quality of life for people suffering from neurohealth conditions when traditional medication hasn't helped. The NeuroStar Advanced Therapy System is cleared by the U.S. Food and Drug Administration (the "FDA") for adults with MDD, as an adjunct for adults with obsessive-compulsive disorder, and to decrease anxiety symptoms in adult patients with MDD that may exhibit comorbid anxiety symptoms (anxious depression), and as a first line adjunct for the treatment of MDD in adolescent patients aged 15-21. NeuroStar Advanced Therapy is the leading TMS treatment for MDD in adults with more than 6.9 million treatments delivered. NeuroStar is backed by the largest clinical data set of any TMS treatment system for depression, including the world's largest depression outcomes registry. Neuronetics is committed to transforming lives by offering an exceptional treatment that produces extraordinary results. For safety and prescribing information, NeuroStar.com.MALVERN, Pa., Nov. 20, 2024 (GLOBE NEWSWIRE) -- Neuronetics, Inc. (NASDAQ: STIM), a medical technology company focused on designing, developing, and marketing products that improve the quality of life for patients who suffer from neurohealth disorders, today announced that the management team will present at the Piper Sandler 36th Annual Healthcare Conference on Wednesday, December 4, 2024. The Company is scheduled to present at 2:30pm Eastern Time the same day via webcast.
馬爾文，賓夕法尼亞州，2024年11月20日（全球新聞通訊）-- neuronetics公司（納斯達克：STIM）是一家專注於設計、開發和銷售改善神經健康障礙患者生活質量的醫療科技公司，今天宣佈管理團隊將在2024年12月4日（星期三）派傑投資第36屆年度醫療會議上進行演講。公司定於同一天東部時間下午2:30通過網絡直播進行演講。
A live audio webcast of the presentation will be available online at the investor relations page of the Company's website at ir.neuronetics.com.
該演示的音頻直播將在公司網站的投資者關係頁面 ir.neuronetics.com 上提供。
About Neuronetics
Neuronetics，Inc.相信心理健康和身體健康一樣重要。作爲神經科學的全球領導者，神經優美正在通過其對心理健康的NeuroStar高級療法重新定義患者和醫生的預期。NeuroStar是一種非藥物、非侵入性的治療方法，可以改善神經健康狀況下的生活質量，當傳統藥物無效時。 NeuroStar適用於治療抑鬱發作，在當前情況下，降低那些可能同時表現出共病性焦慮症狀成年患者的焦慮症狀。它也獲得FDA批准作爲輔助治療青少年MDD的患者。NeuroStar Advanced Therapy是治療成人MDD的領先TMS治療，已提供超過640萬次治療。神經優美致力於通過提供卓越的治療，爲患者帶來非凡的療效，以改變生命。有關安全和處方信息，請訪問 。
Neuronetics, Inc. believes that mental health is as important as physical health. As a global leader in neuroscience, Neuronetics is redefining patient and physician expectations with its NeuroStar Advanced Therapy for Mental Health. NeuroStar is a non-drug, noninvasive treatment that can improve the quality of life for people suffering from neurohealth conditions when traditional medication hasn't helped. The NeuroStar Advanced Therapy System is cleared by the U.S. Food and Drug Administration (the "FDA") for adults with MDD, as an adjunct for adults with obsessive-compulsive disorder, and to decrease anxiety symptoms in adult patients with MDD that may exhibit comorbid anxiety symptoms (anxious depression), and as a first line adjunct for the treatment of MDD in adolescent patients aged 15-21. NeuroStar Advanced Therapy is the leading TMS treatment for MDD in adults with more than 6.9 million treatments delivered. NeuroStar is backed by the largest clinical data set of any TMS treatment system for depression, including the world's largest depression outcomes registry. Neuronetics is committed to transforming lives by offering an exceptional treatment that produces extraordinary results. For safety and prescribing information, NeuroStar.com.
neuronetics公司相信心理健康與身體健康同樣重要。作爲神經科學的全球領導者，neuronetics正在重新定義患者和醫生的期望，通過其NeuroStar愛文思控股治療心理健康。NeuroStar是一種非藥物、非侵入性的治療，在傳統藥物未能幫助的情況下，可以改善患有神經健康狀況的人的生活質量。NeuroStar愛文思控股治療系統已獲得美國食品和藥物管理局（「FDA」）的批准，適用於成年抑鬱障礙患者，作爲強迫症成年患者的輔助治療，並減少可能出現共病焦慮症狀（焦慮型抑鬱症）的成年抑鬱症患者的焦慮症狀，以及作爲針對15-21歲青少年抑鬱症患者MDD治療的首要輔助措施。NeuroStar愛文思控股治療是針對成年抑鬱症的領先TMS治療，已提供超過690萬次治療。NeuroStar擁有世界上最大的抑鬱症結果註冊庫，是任何TMS治療系統中最大的臨床數據集。neuronetics致力於通過提供卓越的治療來改變生活，這種治療產生了非凡的效果。有關安全性和處方信息，請訪問 NeuroStar.com。
Investor Contact:
投資者聯繫人：
Mike Vallie or Mark Klausner
ICR Healthcare
443-213-0499
ir@neuronetics.com
Mike Vallie或者Mark Klausner
ICR 醫療保健
443-213-0499
ir@neuronetics.com
Media Contact:
媒體聯繫：
EvolveMKD
646-517-4220
NeuroStar@evolvemkd.com
EvolveMKD
646-517-4220
NeuroStar@evolvemkd.com
譯文內容由第三人軟體翻譯。
